Genetic Determinants of Statin-Associated Myopathy

• Baigent C , KeechA, KearneyPM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493) , 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• The SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med. (2008) (Epub ahead of print).
   Google Scholar
• Antons KA , WilliamsCD, BakerSK, PhillipsPS: Clinical perspectives of statin-induced rhabdomyolysis.Am. J. Med.119(5) , 400–409 (2006).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM , CorsiniA, DavidsonMH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Inter. Med.163(5) , 553–564 (2003).
   PubMedGoogle Scholar
• Gaist D , RodriguezLA, HuertaC, HallasJ, SindrupSH: Lipid-lowering drugs and risk of myopathy: a population-based follow-up study.Epidemiology12(5) , 565–569 (2001).
   PubMed Web of Science ®Google Scholar
• McClure DL , ValuckRJ, GlanzM, Murphy JR, Hokanson JE: Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J. Clin. Epidemiol.60(8) , 812–818 (2007).
   PubMed Web of Science ®Google Scholar
• Kashani A , PhillipsCO, FoodyJM et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation114(25) , 2788–2797 (2006).
   PubMed Web of Science ®Google Scholar
• Bradford RH , ShearCL, ChremosAN et al.: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am. J. Cardiol.74(7) , 667–673 (1994).
   PubMed Web of Science ®Google Scholar
• de Lemos JA , BlazingMA, WiviottSD et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA292(11) , 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Soininen K , NiemiM, KilkkiE, Strandberg T, Kivisto KT: Muscle symptoms associated with statins: a series of twenty patients. Basic Clin. Pharmacol. Toxicol.98(1) , 51–54 (2006).
   PubMed Web of Science ®Google Scholar
• Vladutiu GD , SimmonsZ, IsacksonPJ et al.: Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve34(2) , 153–162 (2006).
   PubMed Web of Science ®Google Scholar
• Downs JR , ClearfieldM, WeisS et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA279(20) , 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Graham DJ , StaffaJA, ShatinD et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA292(21) , 2585–2590 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez LA , GonzalezEM, WallanderMA, JohanssonS: The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.Pharmacoepidemiol. Drug Saf. (2008) (Epub ahead of print).
   Google Scholar
• Molokhia M , McKeigueP, CurcinV, MajeedA: Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class using case-crossover approach from 1991–2006.PLoS ONE3(6) , E2522 (2008).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326) , 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS , DahlofB, PoulterNR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT–LLA): a multicentre randomised controlled trial. Lancet361(9364) , 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Staffa JA , ChangJ, GreenL: Cerivastatin and reports of fatal rhabdomyolysis.N. Engl. J. Med.346(7) , 539–540 (2002).
   PubMed Web of Science ®Google Scholar
• Clayton D , McKeiguePM: Epidemiological methods for studying genes and environmental factors in complex diseases.Lancet358(9290) , 1356–1360 (2001).
   PubMed Web of Science ®Google Scholar
• Molokhia M , McKeigueP: EUDRAGENE: European collaboration to establish a case–control DNA collection for studying the genetic basis of adverse drug reactions.Pharmacogenomics7(4) , 633–638 (2006).
   PubMed Web of Science ®Google Scholar
• Wilke RA , LinDW, RodenDM et al.: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov.6(11) , 904–916 (2007).
   PubMed Web of Science ®Google Scholar
• Hoggart CJ , ParraEJ, ShriverMD et al.: Control of confounding of genetic associations in stratified populations. Am. J. Hum. Genet.72(6) , 1492–1504 (2003).
   PubMed Web of Science ®Google Scholar
• Pritchard JK , StephensM, RosenbergNA, DonnellyP: Association mapping in structured populations.Am. J. Hum. Genet.67(1) , 170–181 (2000).
   PubMed Web of Science ®Google Scholar
• Fiegenbaum M , da Silveira FR, van der Sand CR et al.: The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther.78(5) , 551–558 (2005).
   PubMed Web of Science ®Google Scholar
• Zuccaro P , MombelliG, CalabresiL, BaldassarreD, PalmiI, SirtoriCR: Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.Pharmacol. Res.55(4) , 310–317 (2007).
   PubMed Web of Science ®Google Scholar
• Frudakis TN , ThomasMJ, GinjupalliSN, HandelinB, GabrielR, GomezHJ: CYP2D6*4 polymorphism is associated with statin-induced muscle effects.Pharmacogenet. Genomics17(9) , 695–707 (2007).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T , MaB, YuN: The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.Br. J. Clin. Pharmacol.56(1) , 120–124 (2003).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ , NiemiM, BackmanJT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.Clin. Pharmacol. Ther.80(6) , 565–581 (2006).
   PubMed Web of Science ®Google Scholar
• Kivisto KT , KantolaT, NeuvonenPJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.Br. J. Clin. Pharmacol.46(1) , 49–53 (1998).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ , KantolaT, KivistoKT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.Clin. Pharmacol. Ther.63(3) , 332–341 (1998).
   PubMed Web of Science ®Google Scholar
• Hirano M , MaedaK, ShitaraY, SugiyamaY: Drug–drug interaction between pitavastatin and various drugs via OATP1B1.Drug Metab. Dispos.34(7) , 1229–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Ho RH , KimRB: Transporters and drug therapy: implications for drug disposition and disease.Clin. Pharmacol. Ther.78(3) , 260–277 (2005).
   PubMed Web of Science ®Google Scholar
• Hermann M , BogsrudMP, MoldenE et al.: Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin. Pharmacol. Ther.79(6) , 532–539 (2006).
   PubMed Web of Science ®Google Scholar
• Rubio JC , Garcia-ConsuegraI, Nogales-GadeaG et al.: A proposed molecular diagnostic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients. Hum. Mutat.28(2) , 203–204 (2007).
   PubMedGoogle Scholar
• Taroni F , VerderioE, DworzakF, Willems PJ, Cavadini P, DiDonato S: Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat. Genet.4(3) , 314–320 (1993).
   PubMed Web of Science ®Google Scholar
• Vladutiu GD , BennettMJ, SmailD, Wong LJ, Taggart RT, Lindsley HB: A variable myopathy associated with heterozygosity for the R503C mutation in the carnitine palmitoyltransferase II gene. Mol. Genet. Metab.70(2) , 134–141 (2000).
   PubMed Web of Science ®Google Scholar
• Oh J , BanMR, MiskieBA, PollexRL, HegeleRA: Genetic determinants of statin intolerance.Lipids Health Dis.6 , 7 (2007).
   PubMed Web of Science ®Google Scholar
• Ruano G , ThompsonPD, WindemuthA et al.: Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve36(3) , 329–335 (2007).
   PubMed Web of Science ®Google Scholar
• Serruys PW , de Feyter P, Macaya C et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA287(24) , 3215–3222 (2002).
   PubMed Web of Science ®Google Scholar
• Garsa AA , McLeodHL, MarshS: CYP3A4 and CYP3A5 genotyping by pyrosequencing.BMC Med. Genet.6 , 19 (2005).
   PubMed Web of Science ®Google Scholar
• Liu CH , PeckK, HuangJD et al.: Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics6(7) , 731–747 (2005).
   PubMed Web of Science ®Google Scholar
• Kuehl P , ZhangJ, LinY et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet.27(4) , 383–391 (2001).
   PubMed Web of Science ®Google Scholar
• Thompson EE , Kuttab-BoulosH, Witonsky D, Yang L, Roe BA, di Rienzo A: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet.75(6) , 1059–1069 (2004).
   PubMed Web of Science ®Google Scholar
• Cavaco I , PiedadeR, GilJP, RibeiroV: CYP2C8 polymorphism among the Portuguese.Clin. Chem. Lab. Med.44(2) , 168–170 (2006).
   PubMed Web of Science ®Google Scholar
• Muthiah YD , LeeWL, TehLK, OngCE, IsmailR: Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians.J. Clin. Pharm. Ther.30(5) , 487–490 (2005).
   PubMed Web of Science ®Google Scholar
• Rower S , BienzleU, WeiseA et al.: Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in northern Ghana. Trop. Med. Int. Health10(12) , 1271–1273 (2005).
   PubMed Web of Science ®Google Scholar
• Dreisbach AW , JapaS, SigelA et al.: The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am. J. Hypertens.18(10) , 1276–1281 (2005).
   PubMed Web of Science ®Google Scholar
• Scordo MG , CaputiAP, D‘ArrigoC, Fava G, Spina E: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res.50(2) , 195–200 (2004).
   PubMed Web of Science ®Google Scholar
• Yang JQ , MorinS, VerstuyftC et al.: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam. Clin. Pharmacol.17(3) , 373–376 (2003).
   PubMed Web of Science ®Google Scholar
• Scordo MG , AklilluE, YasarU, DahlML, SpinaE, Ingelman-SundbergM: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.Br. J. Clin. Pharmacol.52(4) , 447–450 (2001).
   PubMed Web of Science ®Google Scholar
• Zhao F , LokeC, RankinSC et al.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther.76(3) , 210–219 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SY , SohnKM, RyuJY, YoonYR, Shin JG, Kim JW: Sequence-based CYP2D6 genotyping in the Korean population. Ther. Drug Monit.28(3) , 382–387 (2006).
   PubMed Web of Science ®Google Scholar
• Bradford LD : CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Pharmacogenomics3(2) , 229–243 (2002).
   PubMed Web of Science ®Google Scholar
• Tirona RG , LeakeBF, MerinoG, KimRB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European– and African–Americans.J. Biol. Chem.276(38) , 35669–35675 (2001).
   PubMed Web of Science ®Google Scholar
• Nishizato Y , IeiriI, SuzukiH et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther.73(6) , 554–565 (2003).
   PubMed Web of Science ®Google Scholar
• Komoto C , NakamuraT, SakaedaT et al.: MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab. Pharmacokinet.21(2) , 126–132 (2006).
   PubMed Web of Science ®Google Scholar
• Allabi AC , HorsmansY, IssaouiB, GalaJL: Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a west black African population.Eur. J. Clin. Pharmacol.61(2) , 97–102 (2005).
   PubMed Web of Science ®Google Scholar
• Balram C , SharmaA, SivathasanC, LeeEJ: Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlates.Br. J. Clin. Pharmacol.56(1) , 78–83 (2003).
   PubMed Web of Science ®Google Scholar
• Schaeffeler E , EichelbaumM, BrinkmannU et al.: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet358(9279) , 383–384 (2001).
   PubMed Web of Science ®Google Scholar

Websites

• US FDA; Center for Drug Evaluation and Research: Development and drug interactions: table of substrates, inhibitors and inducers (2006) www.fda.gov/Cder/drug/drugInteractions/default.htm
   Google Scholar
• International HapMap Project www.hapmap.org
   Google Scholar
• EUDRAGENE Project www.eudragene.org
   Google Scholar
• PharmGKB: The Pharmacogenetics and Pharmacogenomics Knowledge Base: data on alleles and their distributions in different ethnic groups www.pharmgkb.org
   Google Scholar